According to a press release issued by the Indian drug maker, as a result of the termination, Dr Reddy#39;s has regained worldwide rights to DFA-02, and is currently evaluating its options to take the programme forward.Dr Reddy#39;s Labs terminates Armis Biopharma#39;s licence for its investigational antibacterial product
According to a press release issued by the Indian drug maker, as a result of the termination, Dr Reddy#39;s has regained worldwide rights to DFA-02, and is currently evaluating its options to take the programme forward.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment